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Summary
Introduction: Bevacizumab is a recombinant humanized anti-VEGF monoclonal antibody. It is an effective treatment 
for epithelial ovarian cancer, both in primary and recurrent disease. The incidence of ovarian cancer increases with advanc-
ing age. Despite the high prevalence of the ovarian cancer in elderly, the management of these patients is often less aggres-
sive than in younger patients. In Croatia, from February 2017, we have opportunity to treat patients with epithelial ovarian, 
fallopian tube, or primary peritoneal cancer with bevacizumab in the first-line and second-line settings. Our aim was to in-
vestigate the safety of bevacizumab administration in patients older than 65 years.
Methods: We have retrospectively analyzed the archive data of 65 patients with epithelial ovarian, fallopian tube, or 
primary peritoneal cancer who started treatment with bevacizumab in primary advanced and in first relapse setting at the 
Department of Gynecologic Oncology in the University Hospital Centre Zagreb in the period from January 2017 to Decem-
ber 2018. Patients were divided in two categories according to age: group 1 (≤65 years) and group 2 (>65 years).
Results: Our analysis included 65 patients:47 (72.3%) patients in group 1 compared with 18 (27.7%) in group 2. Bevaci-
zumab was administered to 39 (60%) patients as first-line treatment and to 26 (40%) patients as second-line treatment. The 
median age was 70 years (range 66-76 years) in group 2 and 55 years (range 35-65 years) in group 1. ECOG status 0 had 44.7% 
of patients in group 1 compared with only 22% in group 2. At the time of diagnosis, elderly patients had presented with at 
least one comorbidity in 94.4% of the cases, compared with 42.6% in group 1. The median number of cycles of bevacizumab 
was 9 in elderly patients and 17 cycles in group 1. Among those patients receiving bevacizumab in the first-line setting, 
median progression free interval (PFI) was 12 months in younger patients versus 7 months in elderly patients. Similarly, 
among those receiving bevacizumab in the second-line setting PFI was 9 months in younger patients versus 1 months in 
elderly patients. The occurrence of non-hematological adverse events did not increase in elderly patients; 51.1% of patients 
in group 1 reported some of non-hematological adverse events versus only 27.8% in elderly patients.
Conclusion: Our experience in treating patients with bevacizumab shows good results with acceptable toxicity and our 
findings suggest that its use in the elderly population should be considered as safe and manageable.
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INTRODUCTION
In recent years, ovarian cancer (OC) became 
the most lethal gynecologic malignancy. According 
to global estimates 295,414 new cases were detected in 
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2018, and 184,799 people were died from the disease 
(1). In Croatia, it is the seventh most common can-
cer among women. The estimated number of new 
ovarian cancer cases in Croatia in 2017 was 449 
with 330 deaths (2). The lack of characteristic 
symptoms and effective screening tests for early 
detection of ovarian cancer has led to delayed di-
agnosis and poor prognosis. The standard treat-
ment of our patients is cytoreductive surgery fol-
lowed by platinum-based chemotherapy (3,4). 
Standard chemotherapy consists of combination 
of paclitaxel 175 mg/m2 and carboplatin AUC 5-6, 
both administered intravenously, every 3 weeks. 
In patients with a disseminated disease, one op-
tion is neoadjuvant chemotherapy with interval 
debulking surgery after three to four cycles of che-
motherapy (3,4,5,6).
Various attempts had been made to improve 
systemic treatments for ovarian cancer. The two 
most promising molecular targeting class of 
agents are anti-angiogenic agents and poly-ADP 
ribose polymerase inhibitors.
Bevacizumab is a monoclonal antibody that 
targets vascular endothelial growth factor. It is 
used in the treatment of many cancers. Bevaci-
zumab is the first targeted therapy approved by 
the European Medicines Agency (EMA) for the 
treatment of the advanced and metastatic ovarian 
cancer, fallopian tube, or primary peritoneal can-
cer stage III or IV in combination with three-week-
ly carboplatin and paclitaxel in the first line thera-
py. It is approved due to the results of two ran-
domized controlled phase III trials: GOG-0218 
and ICON-7 study (7,8). These both studies dem-
onstrated an improvement of progression-free 
survival (PFS), especially in the high-risk ovarian 
cancer population. In the ICON7 trial, a survival 
benefit was observed in an exploratory analysis of 
a high-risk subgroup (FIGO IIIB and IIIC stage 
with residual disease after surgery and patients 
with FIGO IV stage) and in the GOG-0218 trial a 
survival benefit was observed only in patients 
with FIGO stage IV (9,10). Bevacizumab is ap-
proved for first relapse of the disease regardless of 
the time elapsed since previous platinum based 
chemotherapy. Two trials phase III: OCEANS and 
GOG-0213 (11,12,13) showed that bevacizumab 
during chemotherapy (with gemcitabine/carbopl-
atin or paclitaxel/carboplatin) and as maintenance 
therapy improved of PFI in patients with plati-
num-sensitive ovarian cancer. Bevacizumab is 
also approved in patients with platinum resistant 
ovarian cancer according AURELIA phase III trial 
(14). The effectiveness of chemotherapy with bev-
acizumab in patients with platinum-resistant 
ovarian cancer is confirmed in REBECA trial (15).
The incidence of ovarian cancer increases 
with age. Approximately 50% of patients with 
ovarian cancer are older than 65 years (16). The 
population tend to be aging and that is reason 
why the number of older patients with ovarian 
cancer will be increase. Despite the high preva-
lence of the ovarian cancer in elderly and the fact 
that increased age is a negative prognostic factor, 
the management of these patients is often less ag-
gressive than in younger patients. There are sev-
eral reasons for that: expectation of worse tolera-
bility of therapy because of comorbidities and 
poor performance status due to Eastern Coopera-
tive Oncology Group (ECOG) and sometimes 
some older patients decline therapy that is more 
intensive because they choose a better quality of 
life over the duration. Despite that, most studies 
and analyses have shown that older patients can 
tolerate chemotherapy and molecular targeting 
agents at similar dose intensity as younger pa-
tients without a significant impact on quality of 
life (QoL) and increased survival (17,18). Under-
treatment may contribute the shorter survival ex-
pectations in older patients (19,20). Many trials 
did not have include many older people in trial 
because of strict inclusion criteria. Therefore, it is 
important to understand whether toxicity has in-
creased in older patients.
Our aim was to investigate the safety of beva-
cizumab administration in patients older than 65 
years.
METHODS
In a retrospective study, we have analyzed 
the medical data of 65 patients with newly diag-
nosed advanced FIGO IIIB-IV or recurrent epithe-
lial ovarian, fallopian tube, or primary peritoneal 
cancer who received bevacizumab during their 
treatment and who were treated at the Depart-
ment of Gynecology and Obstetrics in the Univer-
sity Hospital Centre Zagreb in the period from 
January 2017 to December 2018. As first line che-
motherapy we administered three-weekly pacli-
taxel (175mg/m2) and carboplatin (area under 
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curve (AUC) 5-6). Bevacizumab (15 mg/kg) is ad-
ministrated during chemotherapy and as mainte-
nance therapy as a single agent, for a total of up to 
22 cycles. As second-line chemotherapy, in pa-
tients with platinum sensitive ovarian cancer is 
administrated carboplatin (AUC4) plus gem-
citabine 1000 mg/m2 or carboplatin (AUC 5-6) plus 
paclitaxel 175 mg/m2 and bevacizumab (15 mg/kg) 
followed by bevacizumab maintenance therapy 
until disease progression. In patients with plati-
num resistant OC, as second-line is administrated 
weekly paclitaxel (80 mg/m2) or topotecan (1.5 
Table1.
Characteristics of the patients
Characterictics 
(N=65)
All cases Group 1  (≤65 years)
Group 2  
(>65 years)
N (%) N(%) N(%)
Age, median  
(years) 60 55 70
Age, range  
(years) 35-76 35-65 66-76
ECOG PS
 0 25 (38%) 21 (45%) 4 (22%)
 1 40 (62%) 26 (55%) 14 (78%)
Comorbidities 
(number)
 0 21 (32%) 20 (42%) 1 (5%)
 1 17 (26%) 14 (30%) 3 (17%)
 2 14 (22%) 9 (19%) 5 (28%)
≥ 3 13 (20%) 4 (9%) 9 (50%)
Comorbidities  
type*
Hypertension 39 (60%) 24 (51%) 15 (83%)
Diabetes 4 (6%) 2 (4%) 2 (11%)
Obesity 8 (12%) 5 (11%) 3 (17%)
CV diseases 9 (14%) 3 (6%) 6 (33%)
GI diseases 6 (9%) 3 (6%) 3 (17%)
Pulmonary 3 (5%) 1 (2%) 2 (11%)
Arthritis 2 (3%) 0 2 (11%)
Other cancer 3 (5%) 3 (6%) 0
Other disease 11 (17%) 5 (11%) 6 (33%)
Primary  
tumor site
Ovary 51 (78%) 41 (88%) 10 (56%)
Fallopian tube 7 (11%) 3 (6%) 4 (22%)
Peritoneum 7 (11%) 3 (6%) 4 (22%)
FIGO stage  
of disease
Stages I-II 1 (2%) 1 (2%) 0
Stage III 47 (72%) 35 (75%) 12 (67%)
 
IIIA 2 (3%) 2 (4%) 0
IIIB 6 (9%) 3 (6%) 3 (17%)
IIIC 39 (60%) 30 (65%) 9 (50%)
Stage IV 17 (26%) 11 (23%) 6 (33%)
IVA 6 (9%) 3 (6%) 3 (16.5%)
IVB 11 (17%) 8 (17%) 3 (16.5%)
Characterictics 
(N=65)
All cases Group 1  (≤65 years)
Group 2  
(>65 years)




carcinoma 58 (88%) 40 (85%) 18 (100%)
Endometrioid
Carcinoma 3 (5%) 3 (6%) 0
Mucinous 
carcinoma 1 (2%) 1 (2%) 0
Clear cell 
carcinoma 1 (2%) 1 (2%) 0
Borderline 
carcinoma 2 (3%) 2 (4%) 0
Tumor grade
Low grade 7 (11%) 7 (15%) O
High grade 58 (89%) 40 (85%) 18 (100%)
BRCA mutation
BRCA1 positive 8 (12%) 8 (17%) 0
BRCA2 positive 1 (2%) 1 (2%) 0
BRCA wild type 56 (86%) 38 (81%) 18 (100%)
Surgical approach at 
primary surgery
PDS 51 (78%) 37 (79%) 14 (78%)
NACT+IDS 14 (22%) 10 (21%) 4 (22%)
Chemotherapy 
regimen
PC-BEV (1st line) 39 (60%) 29 (62%) 11 (61%)
GC-BEV (2nd 
line) 17 (27%) 12 (26%) 5 (28%)
PC-BEV (2nd 
line) 3 (5%) 3 (6%) 0
TOPO-BEV (2nd 
line) 1 (2%) 1 (2%) 0
wPAC-BEV (2nd 
line) 4 (6%) 2 (4%) 2 (11%)
* Some patients have more than one comorbidity
ECOG PS = Eastern Cooperative Oncology Group performance status; 
FIGO = International Federation of Gynecology and Obstetrics; CV diseases 
= cardiovascular diseases; GI diseases = gastrointestinal diseases; PDS = pri-
mary debulking surgery; NACT+IDS = neoadjuvant chemotherapy fol-
lowed by interval debulking surgery; BEV = Bevacizumab; PC = paclitaxel/
carboplatin (three-weekly); GC = gemcitabine/carboplatin; TOPO = topote-
can; wPAC = weekly paclitaxel
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mg/m2 during 5 days every three week) and beva-
cizumab (15 mg/kg 3-weekly) followed by bevaci-
zumab maintenance therapy until disease pro-
gression.
Patients are divided in two categories accord-
ing to age: group 1 (≤65 years) and group 2 (>65 
years). We have analyzed the data: age, ECOG sta-
tus, stage of disease, comorbidities, principle of 
surgery (primary surgery or interval debulking 
surgery), pathohistological type of the tumor, 
number and type of adjuvant chemotherapy, 
number of bevacizumab cycles, side effects related 
to bevacizumab application. Patients were fol-
lowed up until March 2020. Quantitative variables 
Figure 1. Summary of treatment exposure to bevacizumab in the first-line setting
Figure 2. Summary of treatment exposure to bevacizumab in  patients with platinum sensitive ovarian 
cancer in the second-line setting
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were expressed as mean and median values. Qual-
itative variables are expressed as absolute and 
relative frequencies.
RESULTS
Our analysis included 65 patients: 47 (72.3%) 
patients in group 1 compared with 18 (27.3%) in 
group 2. The number of included patients in group 
1 were lower because the total number of treated 
patients older than 65 years was lower than those 
≤65 years, and some of the elderly patients were 
un-fit for bevacizumab therapy (they had more co-
morbidities and poor ECOG status). Bevacizumab 
has been administered to 39 (60%) patients as first-
line treatment and to 26 (40%) patients as second-
line treatment. The median age was 55 years 
(range 35-65 years) in group 1 and 70 years (range 
Figure 3. Summary of treatment exposure to bevacizumab in  patients with platinum resistant ovarian 
cancer in the second-line setting
Table 2.





Number of patients in group 1  
(percentage)
Number of patients in group 2  
(percentage)
All AEs G1/G2 AEs G3/G4 AEs All AEs G1/G2 AEs G3/G4 AEs
Hypertension 10 (25%) 8 (17%) 6 (13%) 2 (4%) 2 (13%) 1 (6.5%) 1 (6.5%)
Venous thromboembolic events 4 (6%) 2 (4%) 2 (4%) 0 2 (13%) 1 (6.5%) 1 (6.5%)
Ilues 3 (5%) 3 (6%) 1 (2%) 2 (4%) 0 0 0
Proteinuria 9 (14%) 8 (17%) 8 (17%) 0 1 (6.5%) 1 (6.5%) 0
Vesicovaginal fistula 1 (2%) 1 (2%) 0 1 (2%) 0 0 0
Headache 3 (5%) 3 (6%) 2 (4%) 1 (2%) 0 0 0
Tachycardia 1 (2%) 1 (2%) 1 (2%) 0 0 0 0
Bleeding 2 (3%) 2 (4%) 2 (4%) 0 0 0 0
Creatinine increase 2 (3%) 1 (2%) 1 (2%) 0 1 (6.5%) 1 (6.5%) 0
*Some patients experienced more than one adverse event
CTCEA v.5.0= Common Terminology Criteria for Adverse Events version 5.0; AEs= adverse events; G= grade
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66-76 years) in group 2. ECOG status 0 had 44.7% 
of patients in group 1 compared with only 22% in 
group 2. The primary tumor site in the most pa-
tients were ovary (78%). The majority of patients 
presented with FIGO stage IIIC at diagnosis (39 
patients- 61%) and with serous subtype (89%). 
Stage distribution were similar among older and 
younger patients. All patients in group 2 had se-
rous type of cancer as the most patients in group 1, 
but small percentage in group 1 had also different 
subtypes of cancer. At the time of diagnosis, elder-
ly patients had presented with at least one comor-
bidity in 94.4% of the cases, compared with 42.6% 
in group 1. The most common comorbidity was 
hypertension in both groups (Table1).
The majority of patients (60%) received beva-
cizumab in the first-line setting, with three-weekly 
paclitaxel/carboplatin chemotherapy followed as 
maintenance therapy. In all patients, the median 
number of cycles of bevacizumab was 9 in elderly 
patients and 17 cycles in group 1. In the first-line 
setting, the median number of applicated cycles of 
Table 3.
Bevacizumab in first-line setting
Study Phase Patients Treatment 











Burger et al. (7)
Tewari et al. (10)
III FIGO stage III-IV(n=1873)
Carboplatin + paclitaxel  




Carboplatin + paclitaxel  
+ bevacizumab 15 mg/kg 





Carboplatin + paclitaxel  
+ bevacizumab 15 mg/kg 







Perren et al. (8)
Oza et al. (9)
III
FIGO stage I-II grade 
3 or clear cell subtype 
or FIGO stage IIB-IV
(n=1528)
Carboplatin + paclitaxel 17.4 44.6 10.5 34.5
Carboplatin + paclitaxel  
+ bevacizumab 7.5 mg/kg 
for 12 months
19.8 45.5 15.9 39.3
FIGO= International Federation of Gynecology and Obstetrics; NA= not available; PFS= progression free survival; OS= overall survival
Table 4.
Bevacizumab in second-line setting










Carboplatin + gemcitabine 8.4
0.84
32.9
0.95Carboplatin + gemcitabine  
+ bevacizumab 12.4 33.6
GOG-213






Carboplatin + paclitaxel 10.4
0.61
37.3
0.82Carboplatin + paclitaxel  
+ bevacizumab 13.8 42.2
AURELIA







(weekly paclitaxel,  






(weekly paclitaxel, PLD  
or topotecan) + bevacizumab
6.7 16.6
OC= ovarian cancer, PFS= progression free survival; OS= overall survival; HR= hazard ratio; PLD= pegylated liposomal doxorubicin
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bevacizumab was 18 cycles in group 1 and 11 cy-
cles in group 2 (Figure 1.) In patients with plati-
num sensitive OC who received bevacizumab in 
the second-line therapy, the median number of 
applicated cycles of bevacizumab was 13 in group 
1 and 7 cycles in group 2 (figure 2.). Similarly, in 
patients with platinum resistant OC, the median 
number of bevacizumab’s cycles was 9 in group 1 
and 3 in elderly patients (Figure 3).
Among those patients receiving bevacizum-
ab in the first-line setting, median progression free 
interval (PFI) was 12 months in younger patients 
versus 7 months in elderly patients. Similarly, 
among those receiving bevacizumab in the sec-
ond-line setting PFI was 9 months in younger pa-
tients versus 1 months in elderly patients. The oc-
currence of non-hematological adverse events did 
not increase in elderly patients; 51.1% of patients 
in group 1 reported some of non-hematological 
adverse events versus only 27.8% in elderly pa-
tients. The most common adverse event in both 
groups was hypertension (table 2.)
DISCUSSION
In Croatia, bevacizumab has been established 
in the treatment of ovarian cancer since 2017. In 
first line setting, we have opportunity to treat pa-
tients with bevacizumab if it is found locally ad-
vanced disease (FIGO stage IIIB or IIIC) with re-
sidual disease after surgery and in metastatic dis-
ease (FIGO stage IV) according to results from 
GOG-0218 and ICON7 trials (7,8,9,10). Details of 
the studies about first-line setting are summarized 
in table 3. In second- line setting, we can treat pa-
tients with bevacizumab regardless off time 
elapsed since the first line chemotherapy accord-
ing to results from OCEANS and AURELIA trials 
(11,13,14). The characteristics of the studies are 
summarized in table 4.
Overall, bevacizumab is generally well toler-
ated. Its toxicities are not usually overlapping 
with those of cytotoxic chemotherapy, but may 
add to the adverse events commonly seen with 
chemotherapy. The majority of adverse events are 
mild in severity and manageable, but some do 
 result in significant morbidity. Many adverse 
events associated with bevacizumab were ob-
served during clinical trials like hypertension, 
proteinuria, thromboembolism, gastrointestinal 
events, wound healing complications and others 
(7,8,11,12,14,15,17). Liang in his meta-analysis 
showed that the use of angiogenesis inhibitors 
was associated with a statistically increased risk in 
four of the adverse outcomes studied: arterial 
thromboembolic events, gastrointestinal perfora-
tion, proteinuria, and hypertension (21). Hyper-
tension was the most common adverse event as-
sociated with bevacizumab treatment. Hyperten-
sion occurred in 12 to 41% of patients with 
bevacizumab and it occurred more frequently in 
the frontline bevacizumab treatment group than 
in the recurrence treatment group (7,8,11,14,22).
The elderly patients are often undertreated. 
The study from the FRANCOGYN group demon-
strated that 77% of the younger women received 
optimal treatment compared with 51% of the old-
er women. The older women. They demonstrated 
that patients older than 75 years had less aggres-
sive surgery procedure, and that they received 
more chemotherapy with carboplatin only and 
less bevacizumab (23). A recent French study 
(EWOC-1 trial) showed that in elderly patients 
with ovarian cancer, carboplatin monotherapy or 
weekly carboplatin plus paclitaxel are often pro-
posed as an alternative to three-weekly carbopla-
tin/paclitaxel, but they showed that compared to 
the three-weekly and weekly carboplatin plus pa-
clitaxel regimens, the carboplatin single agent was 
reported to be less active with a significantly 
worse survival outcome in vulnerable elderly pa-
tients, and carboplatin/paclitaxel remains a stan-
dard of treatment (24). Therefore, undertreatment 
contributed to shorter survival in elderly patients. 
In order to avoid exclusion of older patients from 
bevacizumab therapy, it is important to investi-
gate tolerability and safety of bevacizumab in 
those patients.
In our study, we evaluated tolerability of 
bevacizumab therapy in older patients with ovar-
ian cancer. Our findings suggest that older pa-
tients with ovarian cancer generally tolerated bev-
acizumab therapy as well as younger patients. In 
our study, the patients aged >65 years did not 
have more adverse events than younger one.
Data about use of bevacizumab in elderly pa-
tients in first-line settings are available from the 
ROSIA, OTILIA and TURBO trials. All three trials 
agree that bevacizumab can be safely considered 
in the frontline treatment irrespective of age 
(17,25,26). The ROSIA trial evaluated the safety 
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and efficacy of extending bevacizumab therapy 
beyond 15 months in non-progressive ovarian 
cancer patients. That trial demonstrated that in 
bevacizumab-treated ovarian cancer patients aged 
≥70 years, the incidences of low-grade diarrhea 
and grade ≥3 hypertension, thromboembolic 
events, and asthenia were higher than those in pa-
tients aged <70 years . Median PFS was similar in 
both groups despite worse prognosis in older pa-
tients. The conclusion of this study was that older 
age should not preclude use of bevacizumab for 
ovarian cancer in carefully selected patients aged 
≥70 years. (17). The TURBO trial suggests that age 
per se is not a predictive factor of adverse events 
for patients receiving bevacizumab. They suggest 
that predictive factors for increased toxicity are 
higher creatinine serum level (>1.1 g/dl), estimat-
ed glomerular filtration rate (eGFR) ≤60 ml/min 
and ≥3 comorbidities (26).
There are several trials which evaluated use 
of bevacizumab in elderly patients with recurrent 
ovarian cancer (26,27,28). Subgroup analysis of 
the AURELIA trial demonstrated that older pa-
tients aged ≥65 years experienced more often hy-
pertension grade ≥3 with similar improvements in 
response rates. There was no excess of other ad-
verse events of specific interest for bevacizumab 
in older women.
Beinse in his trial demonstrated that older 
women aged ≥70 years experienced more often 
hypertension grade ≥3 if they had baseline hyper-
tension but not in patients without baseline hy-
pertension. In his trial, other adverse events were 
similar in both groups (28).
Our findings suggest that older patients aged 
>65 years with ovarian cancer did not have more 
adverse events than younger patients and perhaps 
the reason for that is lower number of applicated 
cycles of bevacizumab in older patients. In most 
patients, the main reason for bevacizumab inter-
ruption was disease progression, not toxicity. 
Hence, bevacizumab is an active and tolerable 
front-line treatment option that should be consid-
ered irrespective of age.
CONCLUSION
In Croatia, from February 2017 we have op-
portunity to treat patients with epithelial ovarian, 
fallopian tube, or primary peritoneal cancer with 
bevacizumab in the first-line and second-line set-
tings. Our experience in treating patients with 
bevacizumab shows good results with acceptable 
toxicity and our findings suggest that its use in the 
elderly population should be considered as safe 
and manageable.
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PODNOŠLJIVOST BEVACIZUMABA U BOLESNICA STARIJE DOBI OBOLJELIH OD RAKA JAJNIKA:  
ISKUSTVO ZAVODA ZA GINEKOLOŠKU ONKOLOGIJU U KLINIČKOM BOLNIČKOM CENTRU ZAGREB
K. Katić, V. Matković, J. Lešin, G. Vujić i A. Ćorušić
Uvod: Bevacizumab je rekombinantno humanizirano anti-VEGF monoklonsko antitijelo. Učinkovit je u liječenju epitel-
nog raka jajnika, kako u primarnom liječenju tako i kod pojave recidiva bolesti.
Incidencija raka jajnika povisuje se sa starosnom dobi. Unatoč velikoj prevalenciji raka jajnika u starijih osoba, liječenje 
starijih bolesnica često je manje agresivno nego kod mlađih bolesnica. U Hrvatskoj, od veljače 2017. imamo mogućnost lije-
čenja bevacizumabom u bolesnica s epitelnim rakom jajnika, jajovoda i primarnim peritonealnim rakom, kako u prvolinij-
skom liječenju tako i u prvom recidivu bolesti. Cilj nam je bio istražiti sigurnost primjene bevacizumaba u bolesnica starijih 
od 65 godina.
Metode: Retrospektivno, analizirali smo medicinske podatke 65 bolesnica s epitelnim rakom jajnika, jajovoda ili pri-
marnim peritonealnim rakom koji su započeli liječenje bevacizumabom u prvolinijskom liječenju u bolesnica s uznapredo-
valom bolesti kao i prvom recidivu bolesti u Zavodu za ginekološku onkologiju, KBC Zagreb u razdoblju 01.01.2017. do 
31.12.2018. Bolesnice su bile podijeljene u dvije skupine prema dobi: skupina 1 (≤65 godina) i skupina 2 (>65 godina).
Rezultati: U naše istraživanje bilo je uključeno 65 bolesnica: 47 (72,3%) bolesnica u skupini 1 u usporedbi s 18 (27,7%) 
u skupini 2. Bevacizumab je primijenjen kod 39 (60%) bolesnica kao prvolinijsko liječenje te kod 26 (40% ) bolesnica kao 
drugolinijsko liječenje. Medijan dobi bio je 55 godina (raspon 35-65 godina) u skupini 1 i 70 godina (raspon 66-76 godina) u 
skupini 2. ECOG status 0 imalo je 44,7% bolesnica u skupini 1 u usporedbi sa samo 22% u skupini 2. U vrijeme postavljanja 
dijagnoze, u starijih bolesnica zabilježen je barem jedan komorbiditet u 94,4% slučajeva, u usporedbi s 42,6% u skupini 2. 
Medijan broja apliciranih ciklusa bevacizumaba bio je 9 u bolesnica starijih od 65 godina , a 17 apliciranih ciklusa u skupini 
1. U bolesnica koji su primale bevacizumab kao prvolinijsko liječenje, medijan intervala bez progresije bolesti (PFI) bio je 12 
mjeseci u skupini 1 u odnosu na 7 mjeseci u bolesnica starijih od 65 godina. Slično tome, među onima koji su primali beva-
cizumab u drugoj liniji liječenja medijan PFI bio je 9 mjeseci u mlađih bolesnica u odnosu na 1 mjesec u bolesnica starijih od 
65 godina. Pojava ne-hematoloških nuspojava nije se povećala u starijih bolesnika; 51,1% bolesnica u skupini 1 prijavilo je 
neku ne-hematološku nuspojavu nasuprot samo 27,8% u starijih bolesnica.
Zaključak: Naše iskustvo liječenja bolesnica bevacizumabom pokazuje dobre rezultate s prihvatljivom toksičnošću, a 
naše istraživanje sugerira da je primjena bevacizumaba sigurna i podnošljiva i u bolesnica starijih od 65 godina.
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